⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2024Open Access

Table 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC

Mari Nakazawa Mike Fang Tyrus Vong Jane Zorzi Paige Griffith Robert A. Anders Kiyoko Oshima Amy K. Kim Jacqueline Laurin Kelly J. Lafaro Christopher R. Shubert William R. Burns Jin He Richard A. Burkhart Benjamin Philosophe Jeffrey Meyer Robert P. Liddell Christos Georgiades Kelvin Hong Won Jin Ho Marina Baretti Alexandra T. Strauss Mark Yarchoan

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Baseline characteristics of patients who underwent ICI-based neoadjuvant therapy or upfront resection for HCC

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nakazawa et al. (2024) studied this question.

synapsesocial.com/papers/68e5c1f0b6db643587559c22 https://doi.org/10.1158/2767-9764.26687802.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC2024
2Table 3 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC2024
3Table 3 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC2024
4Table 2 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC2024
5Table 2 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC2024

Data from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC2024
Supplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC2024
Supplementary Figure 1 from Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC2024